Felipe Couñago1, Elia del Cerro1, Manuel Recio2, Ana Aurora Díaz1, Francisco José Marcos1, Laura Cerezo3, Antonio Maldonado4, José Manuel Rodríguez-Luna5, Israel Thuissard6, José Luis R Martin7. 1. a 1 Departments of Radiation Oncology, Hospital Universitario Quirón , Madrid, Spain. 2. b 2 Departments of Radiology, Hospital Universitario Quirón , Madrid, Spain. 3. c 3 Department of Radiation Oncology, Hospital Universitario La Princesa , Madrid, Spain. 4. d 4 Department of Nuclear Medicine, Hospital Universitario Quirón , Madrid, Spain. 5. e 5 Departments of Urology, Hospital Universitario Quirón , Madrid, Spain. 6. f 6 Department of Research, Universidad Europea , Madrid, Spain. 7. g 7 Clinical Department, Faculty of Biomedicine, Universidad Europea , Madrid, Spain.
Abstract
OBJECTIVE: The aims of this study were to evaluate the role of 3 tesla multiparametric magnetic resonance imaging (3TmMRI) without endorectal coil in the detection of radiographic local recurrences (rLRs) in a contemporary cohort of patients with prostate cancer who presented with biochemical recurrence after radical prostatectomy (RP) with low prostate-specific antigen (PSA) levels, and to identify clinical parameters associated with the 3TmMRI findings. MATERIALS AND METHODS: Between 2009 and 2013, 57 patients with biochemical recurrence of prostate cancer after RP who were considered for salvage radiation therapy (SRT) were included. 3TmMRI with T2-weighted imaging, diffusion weighted imaging (DWI) and dynamic contrast-enhanced imaging without endorectal coil was carried out in all patients before treatment. RESULTS: In 14 out of 57 patients (24.56%) local recurrence was detected through 3TmMRI. Median pre-SRT PSA was 0.40 ng/ml (interquartile range 0.30-2.05 ng/ml). The recurrence was perianastomotic in eight out of 14 patients (57.14%) and retrovesical in six out of 14 patients (42.86%). The median size of the local recurrence was 15.2 mm (range 8.0-46.0 mm). The probability of rLR was significantly higher in patients with PSA levels above 0.5 ng/ml [adjusted odds ratio (OR) 6.25, 95% confidence interval (CI) 1.27-30.79, p = 0.02] or PSA doubling time (PSADT) over 14 months (adjusted OR 7.12, 95% CI 1.40-36.25, p = 0.01). CONCLUSIONS: This is the first study to find a significant relationship between the PSADT and the rLR through MRI. Patients with PSADT longer than 14 months or pre-SRT PSA above 0.5 ng/ml benefited most from 3TmMRI. Its routine use could have significant clinical implications for SRT.
OBJECTIVE: The aims of this study were to evaluate the role of 3 tesla multiparametric magnetic resonance imaging (3TmMRI) without endorectal coil in the detection of radiographic local recurrences (rLRs) in a contemporary cohort of patients with prostate cancer who presented with biochemical recurrence after radical prostatectomy (RP) with low prostate-specific antigen (PSA) levels, and to identify clinical parameters associated with the 3TmMRI findings. MATERIALS AND METHODS: Between 2009 and 2013, 57 patients with biochemical recurrence of prostate cancer after RP who were considered for salvage radiation therapy (SRT) were included. 3TmMRI with T2-weighted imaging, diffusion weighted imaging (DWI) and dynamic contrast-enhanced imaging without endorectal coil was carried out in all patients before treatment. RESULTS: In 14 out of 57 patients (24.56%) local recurrence was detected through 3TmMRI. Median pre-SRT PSA was 0.40 ng/ml (interquartile range 0.30-2.05 ng/ml). The recurrence was perianastomotic in eight out of 14 patients (57.14%) and retrovesical in six out of 14 patients (42.86%). The median size of the local recurrence was 15.2 mm (range 8.0-46.0 mm). The probability of rLR was significantly higher in patients with PSA levels above 0.5 ng/ml [adjusted odds ratio (OR) 6.25, 95% confidence interval (CI) 1.27-30.79, p = 0.02] or PSA doubling time (PSADT) over 14 months (adjusted OR 7.12, 95% CI 1.40-36.25, p = 0.01). CONCLUSIONS: This is the first study to find a significant relationship between the PSADT and the rLR through MRI. Patients with PSADT longer than 14 months or pre-SRT PSA above 0.5 ng/ml benefited most from 3TmMRI. Its routine use could have significant clinical implications for SRT.
Authors: Martin T Freitag; Jan P Radtke; Ali Afshar-Oromieh; Matthias C Roethke; Boris A Hadaschik; Martin Gleave; David Bonekamp; Klaus Kopka; Matthias Eder; Thorsten Heusser; Marc Kachelriess; Kathrin Wieczorek; Christos Sachpekidis; Paul Flechsig; Frederik Giesel; Markus Hohenfellner; Uwe Haberkorn; Heinz-Peter Schlemmer; A Dimitrakopoulou-Strauss Journal: Eur J Nucl Med Mol Imaging Date: 2016-12-17 Impact factor: 9.236
Authors: Felipe Couñago; Ana Aurora Díaz Gavela; Gemma Sancho; Irene Ortiz; Francisco José Marcos; Manuel Recio; Julio Fernández; Raquel Cano; Mar Jiménez; Israel J Thuissard; David Sanz-Rosa; Juan Castro Nováis; Eduardo Pardo; Yolanda Molina; Hugo Pérez García; Elia Del Cerro Journal: Rep Pract Oncol Radiother Date: 2019-08-08
Authors: Felipe Couñago; Manuel Recio; Antonio Maldonado; Elia Del Cerro; Ana Aurora Díaz-Gavela; Israel J Thuissard; David Sanz-Rosa; Francisco José Marcos; Karmele Olaciregui; María Mateo; Laura Cerezo Journal: Cancer Imaging Date: 2016-12-07 Impact factor: 3.909
Authors: Felipe Couñago; Gemma Sancho; Violeta Catalá; Diana Hernández; Manuel Recio; Sara Montemuiño; Jhonathan Alejandro Hernández; Antonio Maldonado; Elia Del Cerro Journal: World J Clin Oncol Date: 2017-08-10
Authors: D Hernandez; D Salas; D Giménez; P Buitrago; S Esquena; J Palou; P de la Torre; J Pernas; I Gich; G Gómez de Segura; J Craven-Bartle; G Sancho Journal: Radiat Oncol Date: 2015-12-24 Impact factor: 3.481